ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$6.55 USD
+0.11 (1.71%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.54 -0.01 (-0.15%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADMA 6.55 +0.11(1.71%)
Will ADMA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Other News for ADMA
Biotech Alert: Searches spiking for these stocks today
Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Kaitlin Kestenberg Promoted to COO at ADMA Biologics
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target